[
    [
        {
            "time": "2018-04-30",
            "orginal_text": "格隆汇港股聚焦|(4.30)︱重庆银行一季度净利润升9.9%至12.32亿元",
            "features": {
                "keywords": [
                    "重庆银行",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "格隆汇港股聚焦|(4.30)︱重庆银行一季度净利润升9.9%至12.32亿元",
            "scores": {
                "News_content": "格隆汇港股聚焦|(4.30)︱重庆银行一季度净利润升9.9%至12.32亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "A股头条之上市公司公告精选（5.1）",
            "features": {
                "keywords": [
                    "上市公司",
                    "公告",
                    "精选"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "A股头条之上市公司公告精选（5.1）",
            "scores": {
                "News_content": "A股头条之上市公司公告精选（5.1）",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "公告精选：运达股份中标重大项目；药明康德股东拟减持不超11.93%股份",
            "features": {
                "keywords": [
                    "运达股份",
                    "中标",
                    "药明康德",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制造业",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "公告精选：运达股份中标重大项目；药明康德股东拟减持不超11.93%股份",
            "scores": {
                "News_content": "公告精选：运达股份中标重大项目；药明康德股东拟减持不超11.93%股份",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "复星医药：子公司获药品临床试验申请受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "临床试验",
                    "受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星医药：子公司获药品临床试验申请受理",
            "scores": {
                "News_content": "复星医药：子公司获药品临床试验申请受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "复星医药(02196.HK)：凯茂生物治疗肾性贫血药物获药品临床试验申请受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "凯茂生物",
                    "肾性贫血",
                    "药物",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星医药(02196.HK)：凯茂生物治疗肾性贫血药物获药品临床试验申请受理",
            "scores": {
                "News_content": "复星医药(02196.HK)：凯茂生物治疗肾性贫血药物获药品临床试验申请受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "细数2018年研发投入超10亿的中国药企",
            "features": {
                "keywords": [
                    "研发投入",
                    "中国药企",
                    "2018年"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "细数2018年研发投入超10亿的中国药企",
            "scores": {
                "News_content": "细数2018年研发投入超10亿的中国药企",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "医疗保健：市场大幅调整 关注有基本面支撑的优质个股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "市场调整",
                    "基本面",
                    "优质个股"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "医疗保健：市场大幅调整 关注有基本面支撑的优质个股",
            "scores": {
                "News_content": "医疗保健：市场大幅调整 关注有基本面支撑的优质个股",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "平地一声雷！康美药业年报姗姗来迟 营收多计88.98亿",
            "features": {
                "keywords": [
                    "康美药业",
                    "年报",
                    "营收多计"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "平地一声雷！康美药业年报姗姗来迟 营收多计88.98亿",
            "scores": {
                "News_content": "平地一声雷！康美药业年报姗姗来迟 营收多计88.98亿",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "复星医药：第七届董事会第八十四次会议(定期会议)决议公告",
            "features": {
                "keywords": [
                    "复星医药",
                    "董事会",
                    "决议公告"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复星医药：第七届董事会第八十四次会议(定期会议)决议公告",
            "scores": {
                "News_content": "复星医药：第七届董事会第八十四次会议(定期会议)决议公告",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "545股北向资金加仓 两大神奇规律将再显灵 5月看好两板块（名单）",
            "features": {
                "keywords": [
                    "北向资金",
                    "加仓",
                    "规律",
                    "板块"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "545股北向资金加仓 两大神奇规律将再显灵 5月看好两板块（名单）",
            "scores": {
                "News_content": "545股北向资金加仓 两大神奇规律将再显灵 5月看好两板块（名单）",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-01",
            "orginal_text": "复星国际联席总裁、复星医药董事长陈启宇谈复星对产业投资的3次定义",
            "features": {
                "keywords": [
                    "复星国际",
                    "陈启宇",
                    "产业投资",
                    "定义"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "投资"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复星国际联席总裁、复星医药董事长陈启宇谈复星对产业投资的3次定义",
            "scores": {
                "News_content": "复星国际联席总裁、复星医药董事长陈启宇谈复星对产业投资的3次定义",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]